• news.cision.com/
  • Abliva/
  • BioStock: Abliva's CEO – We are the leading programme in mitochondrial disease
English

BioStock: Abliva's CEO – We are the leading programme in mitochondrial disease

Report this content

Abliva is developing drugs for the treatment of mitochondrial diseases, and the company posted positive interim phase II data with its lead candidate KL1333 this summer. Abliva’s CEO Ellen Donnelly stopped by the BioStock Studio to discuss the results and how they impact Abliva's development moving forward.

Watch the interview with Abliva’s CEO Ellen Donnelly at biostock.se:

Abliva's CEO: We are the leading programme in mitochondrial disease - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Subscribe

Documents & Links

Quick facts

BioStock: Abliva's CEO – We are the leading programme in mitochondrial disease
Tweet this